KR102384795B1 - 전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법 - Google Patents

전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법 Download PDF

Info

Publication number
KR102384795B1
KR102384795B1 KR1020167017549A KR20167017549A KR102384795B1 KR 102384795 B1 KR102384795 B1 KR 102384795B1 KR 1020167017549 A KR1020167017549 A KR 1020167017549A KR 20167017549 A KR20167017549 A KR 20167017549A KR 102384795 B1 KR102384795 B1 KR 102384795B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
peptide
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167017549A
Other languages
English (en)
Korean (ko)
Other versions
KR20160085361A (ko
Inventor
요람 데바리
유지엘 샌들러
Original Assignee
임뮨 시스템 키 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임뮨 시스템 키 리미티드 filed Critical 임뮨 시스템 키 리미티드
Publication of KR20160085361A publication Critical patent/KR20160085361A/ko
Application granted granted Critical
Publication of KR102384795B1 publication Critical patent/KR102384795B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020167017549A 2013-12-05 2014-12-04 전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법 Active KR102384795B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (2)

Publication Number Publication Date
KR20160085361A KR20160085361A (ko) 2016-07-15
KR102384795B1 true KR102384795B1 (ko) 2022-04-08

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167017549A Active KR102384795B1 (ko) 2013-12-05 2014-12-04 전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법

Country Status (11)

Country Link
US (1) US9878015B2 (https=)
EP (1) EP3076988B1 (https=)
JP (1) JP6609556B2 (https=)
KR (1) KR102384795B1 (https=)
CN (1) CN105939724B (https=)
AU (1) AU2014358671B2 (https=)
CA (1) CA2931023C (https=)
DK (1) DK3076988T3 (https=)
ES (1) ES2742856T3 (https=)
IL (1) IL245998B (https=)
WO (1) WO2015083167A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411711B1 (en) 2016-02-04 2022-08-03 Immune System Key Ltd. Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
KR20250004754A (ko) * 2022-04-11 2025-01-08 이뮨 시스템 키 엘티디. 증식성 질환의 치료를 위한 bcl2 억제제 및 펩티드 병용 요법
JP7843546B2 (ja) * 2022-05-27 2026-04-10 ジンキュア・コーポレイション 新規なペプチド及びその用途
CN121443625A (zh) * 2023-05-03 2026-01-30 免疫系统密钥有限公司 环状d-肽、其衍生物、组合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507094T3 (es) * 2004-10-25 2014-10-14 Immune System Key Ltd. Proteína específica del timo
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Also Published As

Publication number Publication date
CA2931023A1 (en) 2015-06-11
US9878015B2 (en) 2018-01-30
IL245998B (en) 2019-12-31
KR20160085361A (ko) 2016-07-15
EP3076988B1 (en) 2019-06-05
JP2017505755A (ja) 2017-02-23
ES2742856T3 (es) 2020-02-17
AU2014358671B2 (en) 2019-09-12
WO2015083167A1 (en) 2015-06-11
IL245998A0 (en) 2016-07-31
CN105939724A (zh) 2016-09-14
EP3076988A1 (en) 2016-10-12
DK3076988T3 (da) 2019-09-16
JP6609556B2 (ja) 2019-11-20
CN105939724B (zh) 2020-01-14
AU2014358671A1 (en) 2016-06-02
US20160303200A1 (en) 2016-10-20
CA2931023C (en) 2023-12-19

Similar Documents

Publication Publication Date Title
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
ES2363765T3 (es) Agonistas de fgfr.
JP6921755B2 (ja) 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
UA123392C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу, та його застосування для лікування раку
KR20200100866A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
US12569538B2 (en) DPEP-1 binding compositions and methods of use
ES2897782T3 (es) Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
KR102384795B1 (ko) 전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법
JP7535514B2 (ja) Ｄｐｅｐ－１結合剤および使用の方法
US9789213B2 (en) EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
KR20190064562A (ko) Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
US20250134975A1 (en) Cancer vaccine comprising epitope of c-met and use thereof
KR20230120585A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
KR20230120542A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
WO2026022392A1 (en) Peptide and conjugates thereof
AU2024351102A1 (en) Treatment of cancers associated with beta-catenin
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4